Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Primary Completion Date

March 31, 2006

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

thalidomide

Trial Locations (14)

34

Instituto de Enfermedades Neoplasicas, Lima

2145

Westmead Hospital, Westmead

10466

Comprehensive Cancer Center at Our Lady of Mercy Medical Center, The Bronx

46601

CCOP - Northern Indiana CR Consortium, South Bend

50309

John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines

50314

Mercy Cancer Center at Mercy Medical Center-Des Moines, Des Moines

87131

MBCCOP - University of New Mexico HSC, Albuquerque

85259-5404

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale

50316-2301

Iowa Lutheran Hospital, Des Moines

68128-4157

Midlands Cancer Center at Midlands Community Hospital, Papillion

08903

Cancer Institute of New Jersey, New Brunswick

17033-0850

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey

54307-3453

CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay

00936-7344

San Juan City Hospital, San Juan

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00005966 - Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer | Biotech Hunter | Biotech Hunter